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Abstract
Buruli ulcer, caused by infection withMycobacterium ulcerans, is a necrotizing disease of
the skin and subcutaneous tissue, which is most prevalent in rural regions of West African
countries. The majority of clinical presentations seen in patients are ulcers on limbs that can
be treated by eight weeks of antibiotic therapy. Nevertheless, scarring and permanent dis-
abilities occur frequently and Buruli ulcer still causes high morbidity. A vaccine against the
disease is so far not available but would be of great benefit if used for prophylaxis as well as
therapy. In the present study, vesicular stomatitis virus-based RNA replicon particles
encoding theM. ulcerans proteins MUL2232 and MUL3720 were generated and the expres-
sion of the recombinant antigens characterized in vitro. Immunisation of mice with the
recombinant replicon particles elicited antibodies that reacted with the endogenous anti-
gens ofM. ulcerans cells. A prime-boost immunization regimen with MUL2232-recombinant
replicon particles and recombinant MUL2232 protein induced a strong immune response
but only slightly reduced bacterial multiplication in a mouse model ofM. ulcerans infection.
We conclude that a monovalent vaccine based on the MUL2232 antigen will probably not
sufficiently controlM. ulcerans infection in humans.
Author Summary
Infection withMycobacterium ulcerans can lead to a slow progressing, ulcerative disease of
the skin and underlying soft tissue called Buruli ulcer. The disease is most prevalent in
rural African communities with limited access to health care facilities. The most efficient
means to prevent the disease, a vaccine against Buruli ulcer is not available to date. In the
present study we investigated the immunogenicity and protective potential of a single
cycle virus system expressing the twoM. ulcerans antigens MUL2232 and MUL3720.
Immunization of mice with those vesicular stomatitis virus replicon particles led to the
induction of humoral as well as cellular immune responses in the immunized animals.
Subsequent challenge experiments in a mouse model ofM. ulcerans infection demon-
strated only a limited reduction of bacterial burden in mice immunized with a prime-
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boost approach with MUL2232. Most probably, a vaccine formulation with only one anti-
gen will not be able to provide protection against Buruli ulcer in humans.
Introduction
Mycobacterium ulcerans causes Buruli ulcer (BU), a disease of the skin and underlying subcuta-
neous tissue, which is reported from over 30 countries worldwide [1]. BU is most prevalent in
West African countries and mainly affects children less than 15 years of age, living in remote,
rural areas [2]. The natural reservoir ofM. ulcerans has not been identified so far and also the
mode of transmission of this pathogen remains unclear [3].
M. ulcerans produces a macrolide exotoxin called mycolactone, which induces apoptosis in
mammalian cells and leads to the typical clinical presentation of ulcerative BU skin lesions
after the overlying epidermis has collapsed [4]. Non-ulcerative forms of the disease are nodules
or papules, oedema and plaques [5]. BU was traditionally treated by wide surgical excision of
the affected skin and skin grafting if necessary. Since 2004, treatment of patients for eight
weeks with the antibiotics rifampicin and streptomycin is recommended as standard therapy
by the World Health Organization (WHO) [6]. Even though the use of antibiotics has reduced
recurrence rates to less than 2% [7–9], patients are often left with scars and lifelong disabilities
[10]. A vaccine against BU would therefore be of high value to prevent and treat the disease
[11].
As opposed toM. tuberculosis andM. leprae, which are both intracellular pathogens for
which T helper 1 (TH1) cellular immune responses are essential for infection control [12],M.
ulcerans is found in extracellular clumps in the necrotic subcutaneous skin tissue of advanced
lesions. However, there is evidence for an initial intracellular stage in macrophages during the
early phase of infection [13,14]. Correlates of protection have not been identified, and in partic-
ular it is not known, whether antibodies specific for surface antigens ofM. ulcerans have pro-
tective activity [15].
Vaccination with Bacille Calmette-Guérin (BCG) seems to confer a transient protection
from BU and a shorter duration of ulcers [16–18]. In a mouse model ofM. ulcerans infection,
vaccination with either BCG or a mycolactone-negativeM. ulceransmutant strain delayed the
onset of foot pad swelling [19,20]. A limited protective efficacy has also been achieved with
monovalent DNA-based protein subunit vaccine formulations targeting either the mycolyl-
transferase antigen (Ag) 85A fromM. bovis orM. ulcerans [21,22] or mycolactone polyketide
synthase domains that are encoded on the giantM. ulcerans plasmid pMUM001 [23].
Vesicular stomatitis virus (VSV) is a member of the virus family Rhabdoviridae and has a
non-segmented single-stranded RNA genome of negative polarity. VSV is transmitted by
insects and causes a vesicular-like disease in livestock and Flu-like symptoms in humans. The
VSV seroprevalence is very low in the human population, indicating that human infections are
rare. The non-persisting replication of VSV in the cytosol of the host cell, low virulence and
low pre-existing immunity in humans, and the option of simple genetic manipulation [24] has
recommended VSV as viral vector system for vaccination [25,26]. Several VSV-based vaccines
for protection against viral and bacterial pathogens have been generated in recent years and
have been evaluated in a number of animal models [27–30]. More recently, single-cycle VSV
vectors have been developed, which lack the genetic information for the VSV glycoprotein G
and are complemented with this protein in trans. Although these VSVΔG vectors are restricted
to a single round of infection, they were shown to be as immunogenic as propagation-compe-
tent VSV vectors [31].
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In the present study we used this safe vaccine vector platform to characterize the immuno-
genicity of twoM. ulcerans protein antigens. In view of the mainly extracellular nature ofM.
ulcerans, we chose antigens known to be highly expressed on the surface of the bacteria. The 18
kDa small heat shock protein (MUL2232) was identified amongst the most immunodominant
antigens expressed byM. ulcerans when serum responses from people living in endemic areas
were analysed [32]. A homologue of MUL2232 was found in the genome ofM. leprae but nei-
ther inM. bovis nor inM. tuberculosis. Similar to theM. leprae homologue, MUL2232 is associ-
ated with the cell wall fraction ofM. ulcerans [32,33]. The second antigen chosen, MUL3720, is
a 21 kDa protein with a putative lectin and a peptidoglycoan-binding domain that does not
have homologues inM. leprae orM. tuberculosis [34,35]. It is highly expressed byM. ulcerans
and may play a role in cell attachment and cell-cell interactions [35], making it a candidate
antigen for vaccine development. We generated recombinant single-cycle VSV vectors encod-
ing the selected antigens individually and analysed their expression in mammalian cell lines.
We further analysed the immunogenicity of the generated VSV vectors and evaluated two
short immunization protocols. Finally, we investigated the protective potential of such immu-
nization schemes in an experimental mouse model ofM. ulcerans infection.
Materials and Methods
Ethics statement
All animal experiments were conducted in compliance with the Swiss animal protection law
and approved by the animal welfare committee of the Canton of Basel (authorization number
2375) and the Canton of Vaud (authorization number 2657).
Cells
Baby hamster kidney 21 (BHK-21) cells were obtained from the German Cell Culture Collec-
tion (DSZM, Braunschweig). Cells were grown in Earle’s minimal essential medium (MEM,
Life Technologies) supplemented with 5% foetal bovine serum (FBS, Biowest). BHK-G43, a
transgenic BHK-21 cell line expressing the VSV G protein in an inducible manner, was main-
tained as described previously [36]. Murine L929 fibroblasts (ATCC, The Global Bioresource
Center) were cultivated in RPMI medium (Gibco) supplemented with 10% foetal calf serum
(FCS, Sigma), 2 mM glutamine (Gibco) and 0.05 mM β-mercaptoethanol (Gibco).
Generation of recombinant vesicular stomatitis virus replicon particles
expressingM. ulcerans codon optimized antigens
The potential protein vaccine candidate antigens MUL_2232 (GenBank accession number
4550596) and MUL_3720 (GenBank accession number 4553013) ofM. ulcerans Agy99 were
ordered as codon optimized genes for expression in humans (GenScript) and received in
pUC57 plasmids. For generation of recombinant VSV replicon particles (VRPs), codon opti-
mized target antigens were amplified by PCR and inserted into the pVSVΔG plasmid using
single MluI and BstEII restriction sites upstream and downstream of the fourth transcription
unit, replacing the VSV G gene [37]. Sequence integrity of the resulting plasmids was con-
firmed by Sanger sequencing. Recombinant VRPs were generated as described previously [38].
In brief, BHK-G43 cells were infected with recombinant MVA-T7 virus expressing T7 RNA
polymerase [39]. Subsequently, the infected cells were transfected with plasmids driving T7
RNA polymerase-mediated expression of the VSV proteins N, P, and L, and with pVSVΔG
(MUL2232) or pVSVΔG(MUL3720) driving T7 RNA polymerase-mediated transcription of
VSV antigenomic (negative-sense) RNA. Expression of the VSV G protein was induced by
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adding mifepristone (Sigma) to the cell culture medium. At 24 hours post transfection cells
were detached with trypsin and seeded along with an equal number of fresh BHK-G43 cells
into T-75 flasks. Cells were then incubated at 37°C for another 24 hours in the presence of
mifepristone. Cell culture supernatant was clarified by low-speed centrifugation and by passage
through a 0.2 μm pore filter. The VRPs in the clarified cell culture supernatant were further
propagated on mifepristone-induced BHK-G43 cells and stored at -70°C. VRPs were titrated
on BHK-21 cells taking advantage of the eGFP reporter protein.
Western blot analysis
Detection of vaccine antigens in VRP-infected cells. Equal numbers of confluent L929
fibroblasts were infected with VRPs at a multiplicity of infection (MOI) of 10 for 6 hours at
37°C. Cells were washed with ice-cold phosphate buffered saline (PBS; Sigma) and harvested
for lysis. Protein lysates of both the soluble and insoluble fraction of the cells were produced
with a cell fractionation kit (Abcam) according to the manufacturer’s instructions. Equal
amounts of protein lysates as well asM. ulcerans lysate in an appropriate dilution were resolved
on prefabricated 4–12% gradient gels (NuPAGE Novex 4–12% Bis-Tris Gel; Invitrogen) with
MES running buffer (Invitrogen) according to the manufacturer’s directions. A dry-blotting
system (iBlot; Invitrogen) was used to transfer proteins to nitrocellulose membranes. Mem-
branes were blocked and specific proteins detected with in house anti-MUL2232 or anti-
MUL3720 mouse mAbs followed by HRP-conjugated goat anti-mouse IgG γ-chain mAb
(Southern Biotech, 1030–05). Blots were developed using ECLWestern blotting detection
reagents (ECLWestern blotting Substrate; Pierce).
Cross-reactivity of the elicited antibodies in mouse sera with the native antigen inM.
ulcerans lysate. 10 μg ofM. ulcerans whole cell lysate was resolved on a one well prefabricated
4–12% gradient gel (NuPAGE Novex 4–12% Bis-Tris Gel; Invitrogen) with MES running
buffer according to the manufacturer’s instructions. The blocked membrane was subsequently
cut into thin strips that were individually incubated with appropriate dilutions of serum of
immunized mice for 2 hours. Secondary antibody and development were performed as
described above.
Immunofluorescence analyses
For indirect immunofluorescence analysis, BHK-21 cells were grown on 12 mm diameter cover
slips (2 x 105 cells/well) and infected with VRPs (106 infectious units/well) for 6 hours at 37°C.
Cells were fixed with 3% paraformaldehyde (PFA) and washed with PBS containing 0.1 M of
glycine. The cells were permeabilized with 0.25% (v/v) Triton X-100 and subsequently incu-
bated for 1 hour with anti-MUL2232 or anti-MUL3720 mAbs in appropriate dilutions in 1%
bovine serum albumin (Sigma). For detection of antigen-bound primary antibodies, cells were
incubated with an Alexa Flour 546 labelled anti-mouse IgG secondary antibody (1/500; Molec-
ular Probes, A-11018). The cells were washed with distilled water, embedded in Mowiol 4–88
(Sigma) mounting medium, and analyzed with a Leica TCS SL confocal microscope and LCS
software (Leica Microsystems AG, Glattbrugg, Switzerland).
ELISA on recombinant protein
ELISA plates (Maxisorp; Nunc) were coated with 10ug/ml purified recombinant MUL2232
(rMUL2232) or MUL3720 (rMUL3720) protein produced in Escherichia coli [40]. After block-
ing, plates were incubated with serially diluted sera from immunized mice. Alkaline phospha-
tase-conjugated goat anti-mouse antibody (Sigma) was used as secondary antibody and p-
nitrophenyl phosphate (Sigma) served as substrate. The optical density (OD) of the reaction
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product was measured at 405 nm with a microplate reader (Sunrise Absorbance Reader;
Tecan). The threshold for endpoint titer determination was defined as the double of the mean
measurements plus the mean standard deviation of a dilution series done without primary anti-
body and a dilution series done with pre-bleed serum. Individual serum dilution series were
approximated with sigmoidal dose-response curves and the reciprocal dilution of the intersec-
tion between the curve and the threshold was defined as individual endpoint titer.
Mouse immunization studies
All animal studies were conducted in 8 weeks old female BALB/c mice (Janvier). VRPs (107
fluorescence-forming units) were either applied subcutanously (s.c.) in the neck (for evaluation
of the vaccination protocol) or intramuscularly (i.m.) into the right caudal tight muscle using a
volume of 100 μl or 30 μl, respectively. When several immunizations were conducted, injec-
tions were performed in three week intervals. For prime-boost vaccination regimen, 30 μg of
non-adjuvanted recombinant protein were applied s.c. into the neck. Blood was collected from
the tail vein prior to every immunization as well as 5/6 and 14 days after the protein boost.
Serum was prepared by centrifugation of the blood in SST Microtainer tubes (Becton, Dickin-
son and Company).
Analysis of cellular immune responses
Immunized mice were euthanized 3 weeks after the second immunization. Heart blood was
collected and spleens were aseptically removed and homogenized by passing through a 70 μm
cell strainer (BD Falcon). Cells were then pelleted and red blood cells lysed by incubating the
pellet in red blood cell lysing buffer (Sigma) for 1 minute. Remaining cells were washed several
times with stemline T-cell expansion medium (Sigma) supplemented with 4mM L-Glutamine
(Gibco), 1% Pen-Strep (Gibco), 2.5 ug/ml Amphotericin B (Sigma) and 0.05 mM β-mercap-
toethanol (Gibco) and finally adjusted to 4 x 106 white blood cells/ml. 7.2 x 105 cells per well
were incubated in round-bottom microwell plates (BD Falcon) in a humidified CO2 incubator
and stimulated with Concanavalin A (2 μg/ml, Sigma) as positive control or recombinant pro-
teins at 5 μg/ml. Supernatants were harvested after 24h for Interleukin 2 (IL-2) and 96h for
Interleukin 10 (IL-10) and Interferon gamma (IFNγ) assays and stored frozen at -20°C until
analysis for the selected cytokines. Amount of cytokines in supernatants was determined with
Quantikine ELISA kits for IL-2, IL-10 and IFNγ (R&D Systems).
Challenge infection experiments
TheM. ulcerans strain (S1013) used for the experimental infection of mice was isolated in 2010
from the ulcerative lesion of a Cameroonian BU patient [2]. Bacteria were cultivated for 6
weeks in Bac/T medium (Biomerieux), recovered by centrifugation, and suspended in sterile
PBS to 125 mg/ml wet weight corresponding to 2.8 x 105 CFU/ml as determined by plating
serial dilutions on 7H9 agar plates (Difco). Three weeks after the last immunization, mice were
infected with 30 μl ofM. ulcerans suspension (1/100 of the stock solution in PBS) into the left
hind foot pad. Development of the infection was followed by weekly measurements of the foot
pad thickness with a caliper. At day 60 after experimental infection, mice were sacrificed and
foot pads aseptically removed for enumeration ofM. ulcerans bacteria or histopathology.
Draining inguinal lymph nodes of designated animals were removed and fixed in formalin as
well. AllM. ulcerans infection experiments were conducted under BSL3 conditions.
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Colony forming unit (CFU) plating and enumeration of bacterial load by
real-time PCR (qPCR)
Mouse feet designated for enumeration ofM. ulcerans bacteria were immediately removed
above the ankle after euthanasia, shortly dipped into 70% ethanol, then dried under the laminar
flow, cut in 4 pieces with a scalpel and transferred to 750 μl of Bac/T medium in reinforced
hard tissue grinding tubes (MK28-R, Precellys). Tissue homogenization was performed with a
Precellys 24-Dual tissue homogenizer (3 x 20 s at 5000 rpm with 30 s break), the lysate was
transferred to a new tube and the lysis tube still containing tissue remains was refilled with
750 μl of Bac/T medium. The remains were homogenized a second time and the two lysates
pooled.
CFU plating. 250 μl of the foot pad lysate was decontaminated with 0.5 M NaOH as
described previously [41]. The pellet of decontaminated lysate was dissolved in 500 μl of Bac/T
medium and appropriate dilution series plated on 7H9 agar plates. Following 150 days of incu-
bation at 30°C colonies were counted and the concentration of bacteria expressed as CFU.
DNA extraction and qPCR. DNA from 100 μl of a 1 to 50 dilution of the foot pad lysate
in PBS was extracted as described by Lavender and Fyfe [42]. Extracted DNA was analysed for
IS2404 by qPCR as previously described [42]. Ct values were converted into genome copy
numbers per foot pad by applying the standard curve established for IS2040 by Fyfe et al. [43].
Histopathology
Mouse feet designated for histopathological analysis were removed above the ankle and imme-
diately transferred to 10% neutral-buffered Formalin solution (approx. 4% formaldehyde,
Sigma) for fixation during 24 hours at room temperature. Subsequently, the feet were decalci-
fied in 0.6 M EDTA and 0.25 M citric acid for 12 days at 37°C and transferred to 70% ethanol
for storage and transport. The samples were dehydrated and embedded into paraffin. 5 μm
thin sections were cut, deparaffinised, rehydrated, and stained with Haematoxylin/Eosin (HE,
Sigma, J.T. Baker) or Ziehl-Neelsen/Methylene blue (ZN, Sigma) according to WHO standard
protocols [44]. Stained sections were mounted with Eukitt mounting medium (Fluka). Pictures
were taken with a Leica DM2500B microscope or with an Aperio scanner.
Statistical analysis and image processing
Differences of bacterial load in infected foot pads were statistically analysed by the Mann-
Whitney test using Graph Pad Prism (Version 6.03). Results of cytokine production were sub-
jected to log10 transformation and subsequently analysed with SAS software (SAS Institute,
Cary, USA, release 9.3) using linear mixed models adjusted for random effects. Image process-
ing and picture panel assembly was performed with Photoshop software (Adobe Photoshop
CS6 Extended, version 13.0.1).
Results
Expression of theM. ulcerans vaccine candidate antigens MUL2232 and
MUL3720 by cells infected with recombinant virus replicon particles
Candidate vaccines were generated by replacing the VSV glycoprotein G gene with theM.
ulcerans genes MUL2232 or MUL3720 (Fig 1A). In order to ease virus detection and titration,
the coding sequence for the enhanced green fluorescent protein (eGFP) was inserted as an
additional transcription cassette downstream of theM. ulcerans genes. The recombinant
viruses VSVΔG(MUL2232) and VSVΔG(MUL3720) as well as the control virus VSVΔG,
which only contained the eGFP gene in place of the VSV surface glycoprotein G (Fig 1A), were
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produced and propagated in the helper cell line BHK-G43 providing the VSV G protein in
trans. As expected from other studies with similar constructs, the trans-complemented parti-
cles were able to infect a variety of different mammalian cell lines but were unable to release
progeny viruses [27,45]. We thus refer to them as to virus replicon particles (VRPs).
In order to study the expression of MUL2232 and MUL3720 in infected cells, BHK-21 cells
were infected with the three different VRPs generated and analysed by using MUL2232 and
MUL3720-specific mouse monoclonal antibodies (mAbs) in immunofluorescence microscopy.
Both antigens accumulated in the cytosol of the infected BHK-21 cells (Fig 1B1 and 1B2).
While in the immunofluorescence analysis MUL2232 appeared to be expressed at lower levels
than MUL3720, staining intensities in Western blotting analyses were comparable for both
proteins (Fig 1C). MUL2232 was mainly detected in the soluble fraction of infected L929 fibro-
blasts and to a smaller part in the insoluble fraction (Fig 1C1) while MUL3720 was found in
the soluble fraction only (Fig 1C2). Both proteins co-migrated with the corresponding proteins
inM. ulcerans lysate according to the predicted molecular mass (Fig 1C).
Immunization of mice with virus replicon particles inducesM. ulcerans
cross-reactive antibody responses
To characterize the immune responses elicited by the recombinant VRPs, we compared differ-
ent immunization regimens in BALB/c mice. Humoral immune responses were assessed by
ELISA on immobilized recombinant protein. Sub-cutaneous (s.c.) administration of 107 VRPs
did not lead to measureable antibody responses against the target antigens (Fig 2A and 2B).
However, when VSVΔG(MUL2232) was given i.m., Immunoglobulin (Ig) G antibodies were
elicited in all immunized animals. In contrast, only some mice produced antibodies following i.
m. immunization with VSVΔG(MUL3720) (Fig 2A and 2B). Therefore induction of antibod-
ies solely by i.m. immunization with VSVΔG(MUL3720) was no longer pursued in subsequent
experiments. Independently of the route of administration, both VRPs primed the immune
system, as demonstrated by the fast humoral immune response to an adjuvant-free booster
immunization (s.c.) with 30 μg of the corresponding recombinant protein (Fig 2A and 2B). Six
days after the booster injection, antibody titers were generally higher in mice primed i.m. than
in mice primed s.c. (Fig 2A and 2B). Therefore, only the i.m. route was employed for VRP
administration in subsequent experiments. In addition, a dose of 107 VRPs per immunization
was generally used.
In a next step, we assessed the potential of a shorter prime-boost immunization strategy by
immunizing the animals only once i.m. with VSVΔG(MUL2232) or VSVΔG(MUL3720) and
three weeks later with 30 μg of rMUL2232 or rMUL3720 via the subcutaneous route in the
absence of adjuvant. Five days after the rMUL2232 boost, the ELISA IgG titers were only mar-
ginally higher than those observed prior to the boost, but increased further in the subsequent
two weeks (Fig 3A). On the other hand, administration of rMUL3720 led to high antibody
titers already eight days after the boost (Fig 3C). Importantly, the elicited antibodies were not
only cross-reactive with the recombinant proteins produced in E. coli but also with the target
Fig 1. Expression ofM. ulcerans proteins by VRP-infected cells. (A) Genomemaps of recombinant VSV: The genome of VSV encodes for the
nucleoprotein N, phosphoprotein P, matrix protein M, glycoprotein G, and the large RNA polymerase L. In VSV*ΔG, the glycoprotein G coding region was
replaced by the coding sequence for eGFP. In VSV*ΔG(MUL22332) and VSV*ΔG(MUL3720), the VSV G gene was replaced by theM. ulcerans genes
MUL2232 and MUL3720, respectively. The reporter protein eGFP is encoded by an additional transcription cassette located downstream of theM. ulcerans
genes. (B) BHK-21 cells were infected with the indicated replicons and indirect immunofluorescence analysis performed with mAbs specific for MUL2232
(B1) or MUL3720 (B2) (red fluorescence). The infection of cells with VRPs is indicated by eGFP expression (green fluorescence). Scale bar equals 30 μm.
(C) Equal numbers of L929 fibroblasts were infected with the indicated VRPs at a MOI of 10. At 6 hours post infection, the cells were harvested and protein
lysates of the soluble (s) and insoluble (i) fraction analysed byWestern blotting for expression ofM. ulcerans antigens using mAbs specific for MUL2232 (C1)
and MUL3720 (C2), respectively.
doi:10.1371/journal.pntd.0004011.g001
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proteins expressed byM. ulcerans, as demonstrated by Western blotting onM. ulcerans lysate
(Fig 3B and 3D).
To evaluate whether this immunization regimen would also elicit antigen-specific cellular
immune responses, antigen-specific cytokine secretion of spleen cells was studied in vitro after
primary immunization of mice with VSVΔG(MUL2232) and a second immunization with
either rMUL2232 or VSVΔG(MUL2232). Three weeks after the second immunization, spleen
cells were stimulated with either rMUL2232 or the unrelated rMUL3720 as control. Stimula-
tion with Concanavalin A (ConA) served as positive control for confirming the viability of the
cultured spleen cells. The stimulated cell culture supernatants were analysed by ELISA for the
production of the TH1 cytokine Interferon gamma (IFNγ) (Fig 4A), the pleiotropic [46] cyto-
kine Interleukin 2 (IL-2) (Fig 4B) and the TH2 cytokine Interleukin 10 (IL-10) [47] (Fig 4C).
Overall, no marked difference in terms of cytokine production was observed between the two
immunization schedules. In both cases all three cytokines were produced in significantly higher
amounts when cultured spleen cells were stimulated with the corresponding rMUL2232 anti-
gen. In contrast, stimulation with the unrelated antigen rMUL3720 or mock stimulation had
no significant effect (Fig 4). The most pronounced response was found for IL-10 (Fig 4C), indi-
cating a slight polarization towards a TH2 type response. The same experimental setup with
VSVΔG(MUL3720) was not successful due to technical problems.
Vaccination has no marked inhibitory effect on bacterial proliferation in
an experimental BU mouse model
In a last step, we explored the protective efficacy of the VRP-based immunization in an experi-
mentalM. ulcerans infection model. Groups of six BALB/c mice were immunized according to
the VSVΔG(MUL2232)/rMUL2232 prime-boost regimen or two times i.m. with VSVΔG
(MUL2232). Respective control groups were immunized either with the control VRP VSVΔG
Fig 2. Comparison of immunization routes.Groups of five female BALB/c mice were sequentially immunized with VSV*ΔG(MUL2232) (A) or VSV*Δ
(MUL3720) (B) via the sub-cutaneous (grey dots) or intra-muscular (black dots) route. Prior to every new immunization, blood was taken and serum analysed
by ELISA on the corresponding recombinant proteins (rMUL2232 or rMUL3720). After the third immunization, all mice were boosted (s.c) with the VRP
correspondent, non-adjuvanted recombinant protein. Endpoint total IgG titers were determined for individual animals in one single ELISA. Mean values (line)
± standard deviations are shown.
doi:10.1371/journal.pntd.0004011.g002
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and an rMUL2232 boost (prime-boost control) or twice with VSVΔG (Fig 5). Three weeks
after the last immunization, the left hind foot pad of the mice was infected with 8.4 x 103 M.
ulcerans bacilli. The slowly progressing infection was followed by weekly measurements of the
thickness of the infected foot pads with a caliper (Fig 5A). To determine the bacterial multipli-
cation, mice were euthanized at day 60 after infection and foot pads either processed for histo-
pathological analysis or lysed for enumeration ofM. ulcerans by standard CFU plating.
Quantification was additionally performed by an adapted qPCR method, suitable for the detec-
tion of bacterial proliferation in mouse foot pads over the course of the infection (Fig 5C).
No differences in the kinetics of footpad swelling were observed between immunized mice
and the respective control animals (Fig 5A). However, 60 days post infection the number of
Fig 3. Induction of antigen-specific antibodies by a short prime-boost immunization protocol. Female BALB/c mice (n = 5) were immunized once with
VSV*ΔG(MUL2232) or VSV*ΔG(MUL3720) and boosted with rMUL2232 or rMUL3720 three weeks later. Control animals (n = 5 and n = 3) were immunized
with empty replicon prior to recombinant protein boost three weeks later. (A) Analysis of serially diluted immune sera by ELISA on immobilized rMUL2232.
Mean values (dot) ± standard deviations are shown. (B) Western blotting analysis onM. ulcerans lysate using the indicated immune sera taken three weeks
after protein boost. (C) Analysis of serially diluted immune sera by ELISA on immobilized rMUL3720. Mean values (dot) ± standard deviation are shown. (D)
Western blotting analysis onM. ulcerans lysate using the indicated immune sera taken two weeks after protein boost.
doi:10.1371/journal.pntd.0004011.g003
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Fig 4. Analysis of cellular immune responses. Female BALB/c mice (n = 5) were immunized once with
VSV*ΔG(MUL2232) (i.m.) and boosted with rMUL2232 (s.c., prime-boost) or were immunized with VSV*ΔG
(i.m.) and boosted with rMUL2232 (s.c., prime-boost control). Alternatively, the animals were immunized
twice with either VSV*ΔG(MUL2232) (2 x VRP) or the control vector VSV*ΔG (2 x empty VRP). Three weeks
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CFU per foot pad was slightly but significantly lower in animals immunized with the VRP
prime-protein boost regimen as compared to the prime-boost control immunized animals (Fig
5B). Quantification ofM. ulcerans DNA in the footpads by insertion sequence (IS) 2404 spe-
cific qPCR yielded similar results, i.e. a slight but significant reduction in bacterial multiplica-
tion caused by the VRP prime-protein boost immunization, but not by two subsequent
immunization with VRPs (Fig 5B and 5D). The same experiment with MUL3720 VRPs did not
result in any difference between immunized and control groups (S1 Fig).
A histopathological analysis of representative foot pads confirmed the findings of a slight
reduction of bacterial burden in the VSV prime-protein boost immunized animals as com-
pared to the prime-boost control animals. The non-infected right foot pads served as control
and appeared completely normal (Fig 6A1) with intact muscle tissue (Fig 6A2) and no appar-
ent oedematous changes (Fig 6A3). In comparison, the infected left foot pads of control mice
showed typical histopathological signs of BU with strong oedema (Fig 6B1 and 6B4), necrotic
sole of foot (Fig 6B2), and inflammatory infiltration and extensive haemorrhages all over the
foot pad (Fig 6B3). Ziehl-Neelsen/Methylene blue (ZN) staining revealed large clumps of acid
fast bacilli (AFB) (Fig 6C1), not only located where they were initially injected, but also more
towards the heel of the foot (Fig 6C2) and in the oedematous tissue in the upper part of the
foot pad (Fig 6C5). AFB were associated with remains of infiltrating immune cells (Fig 6C3)
and were also found as fibrous structures in completely necrotic tissue (Fig 6C4). In animals
that received a VRP prime-protein boost immunization, a trend towards a reduction in the
number of AFB clusters was observed (Fig 6D1). Furthermore, AFB appeared to be more often
in close contact with infiltrating cells or were found intracellular (Fig 6D3).
Discussion
Despite substantial control efforts and improvements in treatment and diagnosis, the socioeco-
nomic impact of BU on affected communities remains high. Long treatment regimens with
daily i.m. injections in rural settings of West Africa, late reporting to health facilities, scarring
and resulting permanent disabilities create high morbidity that could be prevented by a vaccine
againstM. ulcerans. Although no such vaccine is available at the moment, reports on self-heal-
ing in patients with early stages of the disease [48,49] as well as sero-epidemiological studies in
BU-endemic countries [32,50] indicate that the human organism is in principle capable of
inducing a protective immune responses against BU. Furthermore, protein subunit vaccination
approaches have demonstrated partial protection in a BU mouse infection model [21,22,51].
In the present study, we used a viral replicon particle system for deliveringM. ulcerans pro-
tein antigens to the immune system. Immunization with a high number of VRPs inducedM.
ulcerans specific antibody responses with i.m. application being superior to s.c. application.
Our VRP prime-recombinant protein boost regimen not only induced a humoral but also a cel-
lular immune response. This is in line with previous work showing that VRPs are able to trigger
humoral as well as cellular immune responses [52].
after the final immunization, mice were euthanized. Spleen cells were taken into culture and stimulated with
either Concanavalin A (ConA), rMUL2232, rMUL3720 or left unstimulated (medium). Levels of secreted
cytokines were determined by commercially available ELISA kits at 24 hours (IL-2, B) and 96 hours (IFNγ, A;
IL-10, C) after stimulation. Mean values (bar) ± standard deviations for 5 mice tested are shown and
expressed as log10 (pg/ml). * p 0.05; ** p 0.01; *** p 0.001; **** p 0.0001 (p–value adjusted for
random effects in a linear mixed model). Ns equals non-significance. # Due to high non-specific rMUL3720
stimulation presumably caused by contaminants in the recombinant protein preparation, values were
normalized to those of a non-immunized group of mice and z-values are depicted for all stimulations except
ConA.
doi:10.1371/journal.pntd.0004011.g004
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The bacterial proteins MUL2232 and MUL3720 were chosen as vaccine antigens because
previous work suggested that these antigens are not only highly immunogenic but also associ-
ated with the outer surface ofM. ulcerans [32,34,35]. Therefore, the strong humoral immune
response observed following immunization of mice was expected to allow antibody-mediated
opsonization of the bacteria with consequent enhanced phagocytosis, complement activation,
Fig 5. Infection of immunized mice withM. ulcerans.Groups of six immunized, female BALB/c mice were infected by s.c. injection ofM. ulcerans
suspension (30 μl) into the left hind foot pad. (A) Development of the infection was followed by weekly measurements of the foot pad thickness with a caliper.
The mean foot pad thickness (dot) ± standard deviation is shown for each animal group. (B) At day 60 after infection, mice were sacrificed and the number of
M. ulcerans bacilli in foot pads determined by classical CFU plating. (C) Quantification ofM. ulcerans in foot pad lysates by IS2404 specific qPCR. Genome
equivalents are shown. (D) Determination ofM. ulcerans genome equivalents in immunized and infected mice. * p 0.05 (Mann-Whitney test).
doi:10.1371/journal.pntd.0004011.g005
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or antibody-dependent cellular cytotoxicity. While we did not observe vaccination-induced
reductions in foot pad swelling in our murineM. ulcerans infection model, assessment of the
Fig 6. Histopathological analysis of mouse foot pads following infection withM. ulcerans. Histological sections of foot pads fromM. ulcerans-infected
mice were stained with Haematoxylin/Eosin (A1-A3, B1-B4) or Ziehl-Neelsen/Methylene blue (ZN) (C1-C5, D1-D3). The right, non-infected foot pad showed
no swelling (A1), intact muscle tissue (A2) and absence of oedema in the upper part of the foot (A3). As opposed to this, the left foot of a mouse immunized
with VSV*ΔG/rMUL2232 (prime-boost control) was strongly swollen 60 days post infection (B1). Cellular infiltration and beginning necrosis of the tissue was
explicitly strong at the base of the foot pad, where bacteria were injected (B2) and muscle fibres started to become destroyed (B3). The upper part of the foot
is highly oedematous (B4). Staining of the same foot pad for AFB revealed large amounts of bacteria in close contact to infiltrating immune cells at the base of
the foot (C3). Appearance of AFB in the destroyed muscle tissue (C4). Big clumps of bacteria were also found towards the ankle of the foot (C2) and in the
oedematous tissue in the upper half of the foot pad (C5). The foot pad of a mouse immunized with VSV*ΔG(MUL2232)/rMUL2232 (prime-boost) contained
large amounts of AFB (D1) which were less spread in the whole foot pad. Intracellular AFB were frequently observed (D3).
doi:10.1371/journal.pntd.0004011.g006
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bacterial load by qPCR as well as CFU plating revealed a slight, but significant reduction in bac-
terial multiplication in VRP prime-protein boost immunized mice. While measurement of foot
pad swelling over time is a parameter that can be followed without euthanizing mice [53,54],
our results illustrate that foot pad swelling not necessarily reflects the extent of bacterial
proliferation.
Despite a slight inhibitory effect on bacterial proliferation, immunization with only one tar-
get antigen in a VRP prime-protein boost regimen was not sufficient to confer full protection
against the experimental infection. Several factors, like the choice or number of antigens
included into the VRPs, could have let to this negative result. Since it is not known, which
immune effector functions are relevant for protection againstM. ulcerans disease [15], it is not
clear whether lack of a strong TH1-polarisation is of major relevance for the failure to achieve a
strong protective efficacy with the immunization regimens tested. One of the advantages of the
replicon system lies in the ability of VSV to tolerate incorporation of long stretches of foreign
DNA into its genome [25,26]. As a modular system, it offers the possibility to design a multiva-
lent subunit vaccine by combining severalM. ulcerans proteins in one replicon. Furthermore
the versatility of the system allows to engineer the location of the expressed protein in the
infected cell, or to target specific immune cells by including genes for co-stimulatory molecules
or receptors to be expressed on the surface of the infected cells [25]. Here we have demon-
strated that RNA replicon particles are a very good delivery system for mycobacterial antigens,
which is in particular encouraging future development of VRP-based multivalent subunit
vaccines.
Supporting Information
S1 Fig. Infection of immunized mice withM. ulcerans (MUL3720 immunizations). Groups
of six immunized, female BALB/c mice were infected into the left hind foot pad with 30 μl of
M. ulcerans suspension (s.c.). (A) Development of the infection was followed by weekly mea-
sures of the foot pad thickness with a caliper. Depicted is the mean foot pad thickness (dot) ±
standard deviation of the individual differently immunized groups. (B) At day 60 after infec-
tion, mice were sacrificed and the number ofM. ulcerans bacilli in foot pads determined by
classical CFU plating. (C) Determination ofM. ulcerans genome equivalents in immunized
and infected mice.
(PDF)
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